[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611521":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":37,"collaborators":40,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":15,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Azienda Ospedaliera di Padova","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Questionnaire","Each enrolled patient will complete quality of life questionnaires, specifically the EORTC QLQ-C30, PAN26, and EQ-5D, at different time points: at enrollment and every 2-3 months after surgery, for up to 2 years.",[13],{"facility":14,"status":15,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"UOC Chirurgia Generale 2, Azienda Ospedale di Padova, Padova, Italy 35128","RECRUITING","Padova","Italy","IT",{"type":20,"coordinates":21},"Point",[22,23],11.14261,44.38225,{"lat":23,"lon":22},[26,31,34],{"name":27,"role":28,"phone":29,"phoneExt":7,"email":30},"Giovanni Marchegiani, MD, PhD, Professor","CONTACT","+390498212259","giovanni.marchegiani@unipd.it",{"name":32,"role":28,"phone":29,"phoneExt":7,"email":33},"Giampaolo Perri, MD, PhD","giampaolo.perri@unipd.it",{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Umberto Cillo, MD, Director, Professor","PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Prof. Umberto Cillo","Chief of General Surgery 2 Department - HBP and liver transplantion unit",[41],{"name":42,"class":6},"University of Padova","100611521","surgery-for-locally-unresectable-pancreatic-cancer-100611521",false,"NCT07241663","Surgery for Locally Unresectable Pancreatic Cancer","Conversion Surgery for Locally Unresectable Pancreatic Cancer - International Multi-center Observational Trial (ROBIN= suRgery for lOcally unresectaBle pancreatIc Cancer)","ROBIN","Inclusion Criteria:\n\n* Patients older than 18 years\n* Patients able to give informed consent\n* Histologically confirmed pancreatic adenocarcinoma\n* LAPC stage according to NCCN10 at diagnosis (Figure 1)\n* Received at least 4 months of induction chemotherapy\n* RECIST 1.1 stable disease (SD) or partial response (PR) after induction therapy\n* Patient considered eligible for radical resection by local MDT\n\nExclusion Criteria:\n\n* Informed consent withdrawal\n* Presence of tumor characteristics precluding surgery\n* Presence of patient significant comorbidities precluding surgery\n* Unavailable pre-induction therapy abdominal imaging\n* Pathological confirmation of any tumor different from PDAC","ALL","18 Years",{"count":54,"type":55},150,"ESTIMATED","OBSERVATIONAL","Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option. This study aims to understand if surgery after such treatments can improve survival and quality of life in selected patients treated at expert centers.",[59],"Locally Advanced Pancreatic Adenocarcinoma",[61,62,63,64,65,66],"Pancreatic cancer","Coversion Surgery Pancreatic Cancer","Quality of Life","Locally advanced PDAC","Unresectable Pancreatic Cancer","Neoadjuvant therapy for pancreatic cancer","2025-11-21",{"date":69,"type":70},"2025-11-26","ACTUAL",{"date":72,"type":70},"2025-01-01",{"date":74,"type":55},"2028-12-31",{"name":5,"class":6},1]